Maged Guirguis, MD
Interventional Pain Medicine · New Orleans, LANPI 1013169549
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Averitas Pharma Inc. at 25.8% of the total. 2025 is the largest year on record at $153,195, 2.2 times the $70,444 reported in 2019. Among interventional pain medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 795 payments — averaging $710.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Averitas Pharma Inc.$146K
- Nevro Corp.$109K
- Avanos Medical$94K
- Boston Scientific$75K
- Pacira Pharmaceuticals Incorporated$34K
- GRT US Holding, Inc.$26K
- plus $81K from 25 others
Across 132 payments — averaging $8834.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$544K
- Boston Scientific$438K
- Avanos Medical$113K
- Abbott$43K
- Nalu Medical, Inc.$18K
- Globus Medical$9K
- plus $1K from 1 others
What the payments were for
- Consulting fees$209,81537%
- Speaking & faculty fees$245,82744%
- Travel & lodging$73,77313%
- Food & beverage$27,4625%
- Education$7,7491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Averitas Pharma Inc. | 197 | $145,727 |
| Nevro Corp. | 152 | $108,816 |
| Avanos Medical | 73 | $93,919 |
| Boston Scientific | 121 | $74,988 |
| Pacira Pharmaceuticals Incorporated | 37 | $34,446 |
| GRT US Holding, Inc. | 13 | $25,787 |
| Saluda Medical Americas, Inc. | 37 | $22,277 |
| Vertex | 15 | $12,672 |
| Tonix Medicines, Inc. | 6 | $11,765 |
| Abbott | 47 | $9,604 |
| Painteq LLC | 22 | $9,364 |
| SPR Therapeutics, Inc | 6 | $5,087 |
| Omnia Medical, LLC | 1 | $2,000 |
| Heron Therapeutics, Inc. | 2 | $1,716 |
| Vertiflex, Inc. | 8 | $1,446 |
| Relievant Medsystems, Inc. | 14 | $1,194 |
| Medtronic(2 entities) | 12 | $877 |
| Spinal Simplicity, LLC | 4 | $520 |
| Si-bone, Inc. | 3 | $452 |
| MML US, Inc. | 3 | $395 |
| Nalu Medical, Inc. | 5 | $380 |
| Biotronik NRO, Inc. | 2 | $271 |
| Brixton Biosciences, Inc. | 2 | $227 |
| Foundation Fusion Solutions, LLC | 1 | $167 |
| Stimwave Technologies Incorporated | 1 | $117 |
| Spine Wave, Inc. | 1 | $115 |
| Tersera Therapeutics LLC | 1 | $113 |
| AbbVie(2 entities) | 5 | $96 |
| Globus Medical | 2 | $40 |
| Stryker | 1 | $30 |
| Convatec Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Qutenza$142,945
- Senza Spinal Cord Stimulation System$56,365
- Omnia$49,568
- GENERATOR$37,290
- Iovera$32,799
- COOLIEF* COOLED RADIOFREQUENCY$30,195
- WaveWriter Alpha Prime 16$26,730
- COOLED RFA$18,037
- Evoke SCS$14,179
- JOURNAVX$12,189
- GENERAL - THERAPIES$10,523
- EXPAREL$10,089
- Zilretta$9,235
- PAINTEQ$8,924
- PROCLAIM$7,818
- Evoke$7,758
- COOLIEF$7,365
- GENERAL PAIN MANAGEMENT$6,369
- SPRINT PNS System$4,950
- SPECTRA WAVEWRITER$3,312
How this compares
$564,626 in reported general payments places this provider in the 95th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 141 | $3,003 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 128 | $2,959 |
| Pregabalin | 240 | $2,360 |
| Tramadol Hcl | 126 | $1,000 |
| Gabapentin | 102 | $948 |
| Duloxetine Hcl | 47 | $649 |
| Celecoxib | 46 | $341 |
| Tizanidine Hcl | 27 | $328 |
| Methocarbamol | 23 | $255 |
| Baclofen | 21 | $244 |
| Oxycodone Hcl | 16 | $176 |
| Meloxicam | 45 | $89 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in New Orleans
- Jessin JohnNew Orleans$8K
- Suneil JollyKenner$107K
- John CefaluShreveport$71K
- Steve LeeSlidell$57K
- William WhyteShreveport$39K
- Paul HubbellMetairie$33K
- Ken EhrhardtHammond$22K
- Thomas BerryLacombe$21K
- Randall BrewerShreveport$19K
- Corey Ann ConnCovinton$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.